Leap Therapeutics, Inc. Forecast, price target & analysts
$0.34
7.23%
day before yesterday
Nasdaq,
May 09, 10:13 pm CET
Leap Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Powered by
Leap Therapeutics, Inc. Classifications & Recommendation:
Hold
100%
Leap Therapeutics, Inc. Price Target
| Target Price | $5.50 |
| Price | $0.34 |
| Potential |
1,541.79%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Leap Therapeutics, Inc. price target 2026.
The average Leap Therapeutics, Inc. target price is $5.50.
This is
1,541.79%
register free of charge
|
|
| A rating was issued by 1 analysts: 0 Analysts recommend Leap Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Leap Therapeutics, Inc. stock has an average upside potential 2026 of
1,541.79%
register free of charge
|
Current Leap Therapeutics, Inc. Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 29 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
